ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS)

27.14
0.81
( 3.08% )
Actualizado: 10:58:56

Calls

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
20.006.907.800.007.350.000.00 %00-
21.006.007.100.006.550.000.00 %00-
22.005.205.900.005.550.000.00 %00-
23.004.204.900.004.550.000.00 %00-
24.003.604.300.003.950.000.00 %00-
25.002.953.303.653.1250.000.00 %01-
26.002.252.702.602.4750.000.00 %05-
27.001.852.102.111.9750.168.21 %22610:44:45
28.001.451.651.551.550.1813.14 %11608:52:30
29.001.101.251.201.175-0.20-14.29 %5411810:23:13
30.000.750.950.880.85-0.32-26.67 %1455610:44:45
31.000.100.700.600.400.000.00 %0168-
32.000.550.700.550.6250.000.00 %0122-
33.000.300.500.300.400.000.00 %037-
34.000.150.350.260.250.000.00 %07-
35.000.100.250.250.1750.014.17 %1002510:56:17
36.000.100.200.170.150.000.00 %03-

Su centro para precios en tiempo real, ideas y debates en vivo

Puts

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
20.000.100.100.100.100.000.00 %010-
21.000.150.150.150.150.000.00 %0256-
22.000.300.300.300.300.000.00 %069-
23.000.050.400.450.2250.000.00 %1408:30:01
24.000.550.650.550.60-0.15-21.43 %561610:44:32
25.000.751.000.850.8750.000.00 %012-
26.001.151.351.551.250.000.00 %0203-
27.001.551.851.971.700.000.00 %0109-
28.002.102.352.352.2250.000.00 %0170-
29.002.753.000.002.8750.000.00 %00-
30.003.503.703.003.600.000.00 %0322-
31.004.104.703.604.400.000.00 %05-
32.004.805.700.005.250.000.00 %00-
33.005.706.405.406.050.000.00 %01-
34.006.507.500.007.000.000.00 %00-
35.007.608.305.407.950.000.00 %018-
36.008.209.300.008.750.000.00 %00-

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TRIThomson Reuters Corporation
US$ 177.26
(784.97%)
66.33k
BCGBinah Capital Group Inc
US$ 3.81
(105.04%)
14.29M
ESGLESGL Holdings Ltd
US$ 1.79
(79.00%)
37.76M
ULYUrgent ly Inc
US$ 0.6482
(54.33%)
132.41M
RRGBRed Robin Gourmet Burgers Inc
US$ 6.10
(34.96%)
2.59M
SUNESUNation Energy Inc
US$ 0.449
(-60.96%)
3.59M
ARKOARKO Corporation
US$ 4.635
(-36.16%)
3.58M
DMRCDigimarc Corporation
US$ 17.43
(-35.54%)
882.39k
SPGCSacks Parente Golf Inc
US$ 0.477
(-34.84%)
6.34M
TNDMTandem Diabetes Care Inc
US$ 22.81
(-32.09%)
6.83M
NVDANVIDIA Corporation
US$ 126.11
(-3.94%)
200.35M
QNRXQuoin Pharmaceuticals Ltd
US$ 0.3465
(12.57%)
138.99M
ULYUrgent ly Inc
US$ 0.6482
(54.33%)
132.41M
TRNRInteractive Strength Inc
US$ 1.37
(9.60%)
119.41M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 12.965
(-2.45%)
87.81M

APLS Discussion

Ver más
Dennisb68 Dennisb68 4 meses hace
IKT is having a great run!
👍️0
Monksdream Monksdream 5 meses hace
APLS at a bottom channel
👍️0
Dennisb68 Dennisb68 1 año hace
$60.00, that didn’t take long!
👍️0
Dennisb68 Dennisb68 1 año hace
I like the way this traded today, $60 in the near future on news?
👍️0
Dennisb68 Dennisb68 1 año hace
Holding up well..
👍️0
doholic11 doholic11 2 años hace
Finally! Back up 14% today.
👍️0
pitacorp pitacorp 2 años hace
Shorts got another 12 to 13% since you're warning, let's hope your warning sticks today...
👍️0
Stockexpertpro Stockexpertpro 2 años hace
APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover
👍️0
IPO$ IPO$ 2 años hace
Closed out of puts at 99% profit on this one. Only three week hold.
👍️0
IPO$ IPO$ 2 años hace
Why is stock up so much???
👍️0
IPO$ IPO$ 2 años hace
Stock up big today.
👍️0
IPO$ IPO$ 2 años hace
FDA announcement soon.
👍️0
IPO$ IPO$ 2 años hace
Puts are very pricey and out of the money. Sell for cash to acct.
👍️0
IPO$ IPO$ 2 años hace
Why up today? As stock goes up, puts go up too. Strange.
👍️0
IPO$ IPO$ 2 años hace
Will we get FDA approval???
👍️0
IPO$ IPO$ 2 años hace
Heavy premium in the puts and calls.
👍️0
IPO$ IPO$ 2 años hace
2/8/23 regulatory decision due on Empavali.
👍️0
conix conix 3 años hace
Huge Market

👍️0
conix conix 3 años hace
Drug trial for dry AMD slows progression of disease

Posted: Tuesday 29 March 2022

A drug being trialled for dry age-related macular degeneration (AMD) can significantly reduce the progression of the disease, according to new studies.

Phase three trials have shown that injections of a drug called pegcetacoplan resulted in a significant reduction in the rate at which the cells of the macular degenerate.

The studies by Apellis Pharmaceuticals built on previous research which showed that dry AMD is linked to the complement system and a hyperactive immune response that damages the eyes. Pegcetacoplan is a complement system inhibitor, meaning it aims to prevent this response from happening and harming healthy cells and tissue.

The studies involved two phase three clinical trials (DERBY and OAKS) involving more than 1,250 patients with late stage dry AMD, often referred to as geographic atrophy (GA). As part of the trials some patients received injections monthly, while others received them every other month.

In the combined results of the two trials, patients who received the drug monthly showed up to a 21% reduction in progression of the disease after 18 months, while those who were injected every other month had a 17% reduction.

Jeffrey S. Heier, principal investigator of the DERBY study from Ophthalmic Consultants of Boston, said: “It is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time. These 18-month results provide further evidence that pegcetacoplan meaningfully slows disease progression and has the potential to preserve vision longer.”

He added: “In my practice, I have seen how devastating it can be for people living with GA to lose more of their vision year after year. There is an urgent unmet need in GA, and these results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease.”

The study also found that pegcetacoplan was generally safe and well tolerated by those on the trial.

Results of the studies are to be submitted to the US Food and Drug Administration (FDA) for review by the end of June 2022, with the hope that the drug will be licenced for use in the USA.
👍️0
PickleNick PickleNick 3 años hace
Going back to 60 this week
👍️0
wantprofits wantprofits 5 años hace
looks like insider dumping may be happening again.. damnit
👍️0
Pedro2004 Pedro2004 5 años hace
Be careful with this company.
There was a great PR.
An insider dump.
Then a 7 million share under-market private placement.
Then another insider dump the next day.

Scam company.
👍️0
ClayTrader ClayTrader 5 años hace
* * $APLS Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ComptonBrosInc ComptonBrosInc 5 años hace
First! Holding $40 2/21 call... waiting on trial results!
👍️0

Su Consulta Reciente

Delayed Upgrade Clock